Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer

Tuesday, August 28, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

CHELMSFORD, Mass., Aug. 28 Magellan Biosciences, anemerging leader in clinical-diagnostics markets worldwide, announced thatSteven E. Diamond, PhD, has joined the company as chief scientific officer.Dr. Diamond comes to Magellan from Siemens Medical Solutions Diagnostics(formerly Bayer Diagnostics), where he was vice president, research anddevelopment, for the point-of-care product lines: urinalysis, blood gas, andHbA1c (diabetes testing). In addition to internal product development, Dr.Diamond had an active role in the evaluation and development of externaltechnologies to enhance and extend the company's products for near-patienttesting.

"Steve has been a true leader in the point-of-care and near-patient-testing arena -- Magellan's primary focus areas for future growth. Under hisstewardship, Bayer successfully developed and launched a suite of market-leading products for near-patient testing. He knows how to shepherd productsfrom concept, through research and development, and onward to product launch -all the way to commercial success," said Magellan President and CEO, Robert J.Rosenthal, PhD. "And he joins Magellan at an ideal time in our companydevelopment. We continue to meet our growth goals, and have an excellent trackrecord of developing and commercializing innovative platform products toimprove outcomes and serve critical unmet needs in the clinical-diagnosticmarket. Recent product introductions include ESA's LeadCare(R) II point-of-care system, designed for community-based testing to identify rapidly childrenwith elevated blood-lead levels; Dynex's DS2(TM) ELISA processing system,which brings the power of automation to hospital-based and other lower-throughput labs, and TREK's new Vizion(TM) system, which adds digital-imagingcapability to its leading Sensititre(R) system for antibiotics-resistancetesting.

Dr. Rosenthal continued, "Steve's charge is to help us build on thissuccess by leveraging our existing technologies and development capabilitiesacross the company. He will play a key role in defining and implementing ourdiagnostic-product portfolio strategy - providing scientific expertise andleadership to help ensure that our product pipeline is compelling, highquality, and delivered in a timely manner to meet market needs. Steve willalso be an active voice in Magellan's acquisition, licensing, and partnershipstrategy -- providing scientific evaluation and counsel in our pursuit ofcomplementary technologies that expand our presence in the point-of-care andhospital-laboratory segments."

Dr. Diamond previously held several senior-level positions at BayerDiagnostics. From 2000-2004, he was vice president research and developmentfor the near-patient-testing segment. Before that, he was vice president,research and development for the self-testing segment. Prior to joining Bayer,he was vice president, research and development for the StratusImmunochemistry business of Baxter Diagnostics. Dr. Diamond received abachelor's degree cum laude in chemistry from Rensselaer Polytechnic Institute(Troy, New York) and a PhD in chemistry from Stanford University (Stanford,California), with Nobel Laureate, Professor Henry Taube, as his researchadvisor. He is the recipient of several honors and awards, has authored manytechnical publications and abstracts in peer-reviewed journals, and is the co-holder of numerous United States and international patents.

About Magellan Biosciences

Magellan serves the worldwide clinical-diagnostics market with rapidpoint-of-care analyzers and automated systems for hospital-based labs andnear-patient testing. Scientists use the company's discovery systems andsensors for cutting-edge research to develop a new understanding of health andillness -- from disease pathology to biomarker identification. Magellandesigns all its systems, sensors, and consumables to deliver better, more-reliable results. And better

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store